June 25th 2024
The treatment of vitiligo has advanced from ancient herbal remedies to the first FDA-approved topical, paving the way for improved management and outcomes.
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Vitiligo Repigmentation Improvements More Noticeable in Patient-Reported Outcome Measures
October 13th 2022Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.
Thyroid Abnormalities Rare Among Children with Vitiligo, Study Finds
September 30th 2022The search for the causes of vitiligo continues. The findings in this study stand in contrast to another one conducted in eastern China that showed a high percentage of children with vitiligo had thyroid abnormalities.
Improvements in Vitiligo Repigmentation More Noticeable in Patient-Reported Outcome Measures
September 8th 2022Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.
How Ruxolitinib Will Change the Future of Vitiligo Treatment
July 21st 2022Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.